The US Food and Drug Administration (FDA) has granted the Gilead Sciences (Nasdaq: GILD) subsidiary Kite a Regenerative Medicine Advanced Therapy Designation (RMAT) for Yescarta (axicabtagene ciloleucel) for adults with newly-diagnosed, high-risk large B-cell lymphoma (LBCL).
Suitable patients are identified through a positive positron emission tomography (PET) scan after two cycles of first-line chemoimmunotherapy. High-risk LBCL is a disease characterized by an aggressive course, early and frequent relapses, and low long-term survival rates.
Since Yescarta was first approved as third-line plus treatment for adult patients with LBCL in 2017, followed by approval as second-line treatment in 2022, Kite has been focused on bringing the curative potential of CAR T-cell therapy as early in patients’ treatment course as possible.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze